
BUILDING AOPS FOR NEUROTOXICITY: PERSPECTIVE FROM AN ACADEMIC

LEIBNIZ-INSTITUT FÜR UMWELT-MEDIZINISCHE FORSCHUNG

Univ.-Prof. Dr. med. Ellen Fritsche



Molecular Targets in Brain Cells







Processes involved in Neurodevelopment




Fig. 1. The stages of brain development (top) and different windows of vulnerability (bottom). Developmental processes occur in phases, setting the stage for potential periods of vulnerability. Insults early in life (bottom) will be assimilated into innervation patterns, whereas a later pre-pubertal insult will cause functional changes that are more adaptive.



LEIBNIZ-INSTITUT FÜR UMWELT-MEDIZINISCHE FORSCHUNG

Identification of AOPs for neurotoxicity

Critical Reviews in Toxicology

http://informahealthcare.com/txc ISSN: 1040-8444 (print), 1547-6898 (electronic)

informa healthcare

Orit Rev Toxicol, 2015; 45(1): 83–91
© 2015 Informa Healthcare USA, Inc. DOI: 10.3109/10408444.2014.981331

REVIEW ARTICLE

Putative adverse outcome pathways relevant to neurotoxicity

Anna Bal-Price¹, Kevin M. Crofton², Magdalini Sachana¹, Timothy J. Shafer², Mamta Behl³, Anna Forsby⁴, Alan Hargreaves⁵, Brigitte Landesmann¹, Pamela J. Lein⁶, Jochem Louisse¹, Horianne Monnet-Tschudi⁷, Alicia Paini¹, Alexandra Rolaki¹, André Schrattenholz⁸, Cristina Suñol⁹, Christoph van Thriel¹⁰, Maurice Whelan¹, and Elen Fritsche¹¹

¹European Commission Joint Research Centre, Institute for Health and Consumer Protection, Ispra, Italy, ²National Center for Computational Toxicology, Office of Research and Development, U.S. Environmental Protection Agency, RTP, USA, ³Division of the National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA, ⁴Department of Neurochemistry, the Arrhenius Laboratories for Natural Science, Stockholm University, Stockholm, Sweden, Swetox, Swedish Toxicology Sciences Research Center, Södertälje, Sweden, ⁵Nottingham Trent University, Nottingham, UK, ⁶Department of Molecular Biosciences, School of Veterinary Medicine, University of California Davis, Davis, California, USA, ⁷Department of Physiology and SCAHT, University of Lausanne, Lausanne, Switzerland, ⁸ProteoSys AG, Mainz, Germany, ⁹Institut d'Investigacions Biomèdiques de Barcelona, IIBB-CSIC, IDIBAPS, CIBERESP, Barcelona, Spain, ¹⁰IfADo-Leibniz Research Center for Working Environment and Human Factors, Dortmund, Germany, and ¹¹IUF-Leibniz Research Institute for Environmental Medicine, Düsseldorf, Germany






Identification of AOPs for neurotoxicity

- I. NMDAR blockage during development induces impairment of cognitive and learning abilities
- **II. NMDA receptor over-a**ctivation mediates neuronal cell death and reduction (or loss) of cognitive, sensory and motor function.
- III. GABA receptor-mediated neurotoxicity results in hyperexcitability and convulsions
- IV. Acute Neurotoxic Effects of Pyrethroids Mediated by Disruption of Voltage-gated Sodium Channels
- V. Binding of chemicals to membrane receptors, enzymes or cytoskeletal proteins results in **delayed neuropathy**
- VI. Impairment of learning and memory induced by binding of electrophilic chemicals to **SH(thiol)-group** of proteins during development
- VII. Inhibition of **mitochondrial respiration** or uncoupling of oxidative phosphorylation decreases or blocks ATP production resulting in neurodegeneration.
- VIII. Multiple molecular initiating events trigger neuroinflammation leading to neurodegeneration
- IX. The developmental neurotoxicity of non-dioxin-like PCBs: Sensitization of **ryanodine receptors** interferes with neurodevelopmental processes that determine neuronal connectivity
- X. ROS-dependent reduced adult neurogenesis due to decline of neural progenitor cell function: higher susceptibility during aging.

The Neurosphere Assay



Fritsche et al. Environ Health Perspect 2005

Moors et al. Toxicol Appl Pharmacol 2007 Moors et al. Environ Health Perspect 2009 Moors et al. Genes & Immunity 2010 Tegenge et al. Cell. Mol. Life Sci. 2010 Schreiber et al. Environ Health Perspect 2010


Gassmann et al. Environ Health Perspect 2010


Verner et al. Toxicol in Vitro 2011
Fritsche et al. Methods Mol Biol 2011
Gassmann et al. Toxicol in Vitro 2012
Bal-Price et al. ALTEX 2012

Baumann et al. Curr. Protoc. Toxicol. 2014
Gassmann et al. Arch. Toxicol. 2014
Fritsche Methods Pharmacol. Toxicol. 2014
Alépée et al. ALTEX 2014
Baumann et al. Arch Toxicol 2016
Baumann et al. Methods Pharmacol
Toxicol 2015
Barenys et al. Arch Toxicol 2017
Schmuck et al., Arch Toxicol 2017
Dach et al., Sci Rep 2017
Hellwig et al. Tox in vitro 2018
Masjosthusmann et al. TAAP 2018
Ali et al. Brain Struct Funct 2019


Masjosthusmann et al. Chemosphere 2019

FÜR UMWELT-MEDIZINISCHE






Radial Glia Migration/Differentiation




EGCG disturbs migration of rat and human NPCs in vitro









EGCG lowers cellular density of human NPCs in vitro












from Ankley et al., 2009





EGCG disturbs migration by interaction with laminin

Suzuki and Isemura, 2001



EGCG-Sepharose 4B column
+ laminin solution → collection 1 mL fractions


Fractions 0-10:

Laminin retained in the column

Fractions 10-20:


Laminin was eluted with a buffer containing 4 M urea and 1 M NaCl

...










from Ankley et al., 2009








Adhesome











EGCG prevents laminin binding to integrin-β1














[µg/mL]


[µg/mL]



from Ankley et al., 2009








from Ankley et al., 2009






EGCG disturbs alignment of radial glia cells








EGCG causes secondary neuronal loss











MEDIZINISCHE FORSCHUNG



MEDIZINISCHE FORSCHUNG

Exposure



Putative, qualitative > quantitative AOP





Pharmacokinetic assessment of EGCG food supplement intake

Pharmacokinetics



EGCG oral supplements available via the Internet:

Concentration
0.1 g EGCG/mL x Dose
= 3 g

From EGCG pharmacokinetics in humans:

Dose C_{max} plasma 1.6 and 2 g EGCG/d 7.4 and 8.7 μ M

Considering **pregnant women**, extrapolating from:

Dose C_{max} maternal plasma 3 g EGCG/d 11.9 to 22.2 µM

From EGCG pharmacokinetics in rats:

 C_{max} maternal plasma C_{max} fetal brain $0.6 \, \mu M$ $0.0761 \, \mu M$

Assuming similar pharmacokinetics in pregnant rats and humans, which is supported by comparable EGCG kinetics in non-pregnant individuals

Dose C_{max} maternal plasma C_{max} fetal brain 3 g EGCG/d 11.9 to 22.2 μ M 1 to 3 μ M

LOAEC hNPCs

- migration $5 \mu M$ - adhesion $1 \mu M$

- GFAP⁺ process orientation 5 μM


cell density

Ullmann et al., 2003 Shanafelt et al., 2009 Chu et al., 2007 Suganuma et al., 1998 Zini et al., 2006

Rev. in Barenys et al. 2015



 $5 \mu M$



- High concentration EGCG disturbs
 NPC migration/adhesion
- MoA: EGCG binds laminin and thereby prevents laminin-integrin binding
- Disturbed adhesion causes altered radial glia alignment
- In vivo, altered integrin function causes structural and functional neurodevelopmental defects
- Pharmacokinetic considerations call for caution of high dose food supplement intake during pregnancy



CHM –天麻 (TM) Non Toxic CHM

- Tian Ma, Gastrodia elata Blume
- Tall Gastrodia Tuber (TGT)






MEDIZINISCHE FORSCHUNG


CHM -雷公藤 (LGT) Strong Toxic CHM


- Lei Gong Teng, Radix Et Rhizoma Tripterygii
 Wilfordii
- Common Threewingnut Root (CTR)












control

0,01mg/ml LGT

0,1 mg/ml LGT


1 mg/ml LGT








Neurosphere exposure towards LGT



control



0,01 mg/mL LGT





Acknowledgements

Dr. Julia Tigges

Dr. Marta Barenys

Dr. Janette Goniwiecha

Dr. Ruola Habibev

Dr. Katharina Dach

Dr. Martin Schmuck

Dr. Maxi Hofrichter

Stefan Masjosthusmann PhD cand

Laura Nimtz PhD cand

Jördis Klose PhD cand

Mohammed Elgamal PhD cand

Farina Bendt

Ulrike Hübenthal

Saskia Wuttke

Anna Wellenberg

Britta Kühne

Barbara Petzuch

Anastasia Geldaris









VIP - Validation of innovative products



Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen











